BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 37827216)

  • 1. Cell Plasticity in a Mouse Model of Benign Prostate Hyperplasia Drives Amplification of Androgen-Independent Epithelial Cell Populations Sensitive to Antioxidant Therapy.
    Dos Santos L; Carbone F; Pacreau E; Diarra S; Luka M; Pigat N; Baures M; Navarro E; Anract J; Barry Delongchamps N; Cagnard N; Bost F; Nemazanyy I; Petitjean O; Hamaï A; Ménager M; Palea S; Guidotti JE; Goffin V
    Am J Pathol; 2024 Jan; 194(1):30-51. PubMed ID: 37827216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH).
    Lai KP; Huang CK; Fang LY; Izumi K; Lo CW; Wood R; Kindblom J; Yeh S; Chang C
    Mol Endocrinol; 2013 Oct; 27(10):1617-31. PubMed ID: 23893956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rate of castration-induced prostate stroma regression is reduced in a mouse model of benign prostatic hyperplasia.
    Zhang R; Singh S; Pan C; Xu B; Kindblom J; Eng KH; Krolewski JJ; Nastiuk KL
    Am J Clin Exp Urol; 2023; 11(1):12-26. PubMed ID: 36923722
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin.
    Kindblom J; Dillner K; Sahlin L; Robertson F; Ormandy C; Törnell J; Wennbo H
    Endocrinology; 2003 Jun; 144(6):2269-78. PubMed ID: 12746285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgens and estrogens in benign prostatic hyperplasia: past, present and future.
    Nicholson TM; Ricke WA
    Differentiation; 2011; 82(4-5):184-99. PubMed ID: 21620560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gene expression analysis of prostate hyperplasia in mice overexpressing the prolactin gene specifically in the prostate.
    Dillner K; Kindblom J; Flores-Morales A; Shao R; Törnell J; Norstedt G; Wennbo H
    Endocrinology; 2003 Nov; 144(11):4955-66. PubMed ID: 12960074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new experimental rat model of erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: the testosterone-supplemented spontaneously hypertensive rat.
    Oudot A; Oger S; Behr-Roussel D; Caisey S; Bernabé J; Alexandre L; Giuliano F
    BJU Int; 2012 Nov; 110(9):1352-8. PubMed ID: 22448674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting androgen receptor to suppress macrophage-induced EMT and benign prostatic hyperplasia (BPH) development.
    Lu T; Lin WJ; Izumi K; Wang X; Xu D; Fang LY; Li L; Jiang Q; Jin J; Chang C
    Mol Endocrinol; 2012 Oct; 26(10):1707-15. PubMed ID: 22915828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Review of the Roles and Interaction of Androgen and Inflammation in Benign Prostatic Hyperplasia.
    Tong Y; Zhou RY
    Mediators Inflamm; 2020; 2020():7958316. PubMed ID: 33192175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 5-Alpha reductase inhibitors induce a prostate luminal to club cell transition in human benign prostatic hyperplasia.
    Joseph DB; Henry GH; Malewska A; Reese JC; Mauck RJ; Gahan JC; Hutchinson RC; Mohler JL; Roehrborn CG; Strand DW
    J Pathol; 2022 Apr; 256(4):427-441. PubMed ID: 34928497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex steroid receptor expression and localization in benign prostatic hyperplasia varies with tissue compartment.
    Nicholson TM; Sehgal PD; Drew SA; Huang W; Ricke WA
    Differentiation; 2013; 85(4-5):140-9. PubMed ID: 23792768
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucocorticoids are induced while dihydrotestosterone levels are suppressed in 5-alpha reductase inhibitor treated human benign prostate hyperplasia patients.
    Jin R; Forbes C; Miller NL; Strand D; Case T; Cates JM; Kim HH; Wages P; Porter NA; Mantione KM; Burke S; Mohler JL; Matusik RJ
    Prostate; 2022 Oct; 82(14):1378-1388. PubMed ID: 35821619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prostaglandin pathway is activated in patients who fail medical therapy for benign prostatic hyperplasia with lower urinary tract symptoms.
    Jin R; Strand DW; Forbes CM; Case T; Cates JMM; Liu Q; Ramirez-Solano M; Milne GL; Sanchez S; Wang ZY; Bjorling DE; Miller NL; Matusik RJ
    Prostate; 2021 Sep; 81(13):944-955. PubMed ID: 34288015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The expression of androgen-responsive genes is up-regulated in the epithelia of benign prostatic hyperplasia.
    O'Malley KJ; Dhir R; Nelson JB; Bost J; Lin Y; Wang Z
    Prostate; 2009 Dec; 69(16):1716-23. PubMed ID: 19676094
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen regulated genes in human prostate xenografts in mice: relation to BPH and prostate cancer.
    Love HD; Booton SE; Boone BE; Breyer JP; Koyama T; Revelo MP; Shappell SB; Smith JR; Hayward SW
    PLoS One; 2009 Dec; 4(12):e8384. PubMed ID: 20027305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen receptor roles in the development of benign prostate hyperplasia.
    Izumi K; Mizokami A; Lin WJ; Lai KP; Chang C
    Am J Pathol; 2013 Jun; 182(6):1942-9. PubMed ID: 23570837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A rare castration-resistant progenitor cell population is highly enriched in Pten-null prostate tumours.
    Sackmann Sala L; Boutillon F; Menara G; De Goyon-Pélard A; Leprévost M; Codzamanian J; Lister N; Pencik J; Clark A; Cagnard N; Bole-Feysot C; Moriggl R; Risbridger GP; Taylor RA; Kenner L; Guidotti JE; Goffin V
    J Pathol; 2017 Sep; 243(1):51-64. PubMed ID: 28603917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epithelial-to-mesenchymal transition and estrogen receptor α mediated epithelial dedifferentiation mark the development of benign prostatic hyperplasia.
    Shao R; Shi J; Liu H; Shi X; Du X; Klocker H; Lee C; Zhu Y; Zhang J
    Prostate; 2014 Jun; 74(9):970-82. PubMed ID: 24752964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regional variations of insulin-like growth factor I (IGF-I), IGF-II, and receptor type I in benign prostatic hyperplasia tissue and their correlation with intraprostatic androgens.
    Monti S; Di Silverio F; Iraci R; Martini C; Lanzara S; Falasca P; Poggi M; Stigliano A; Sciarra F; Toscano V
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1700-6. PubMed ID: 11297606
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Role of Heat Shock Protein 70 Subfamily in the Hyperplastic Prostate: From Molecular Mechanisms to Therapeutic Opportunities.
    Fu X; Liu H; Liu J; DiSanto ME; Zhang X
    Cells; 2022 Jun; 11(13):. PubMed ID: 35805135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.